Trials / Completed
CompletedNCT03078855
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
ILyAD (Indolent Lymphoma And Vitamin D) A Phase III Double Blind, Randomized Trial to Evaluate the Effect of Vitamin D on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 211 (actual)
- Sponsor
- Jonathan Friedberg · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Despite strong evidence suggesting that vitamin D deficiency is associated with undesirable outcomes in patients with numerous cancers, there has never been a thorough study of vitamin D treatment in subjects undergoing treatment for cancer. The purpose of this study is to evaluate whether modification of vitamin D levels in the blood, through supplementation, can improve outcomes.
Conditions
- Follicular Lymphoma
- Small Lymphocytic Lymphoma
- Marginal Zone Lymphoma
- Mucosal-Associated Lymphoid Tissue Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Vitamin D | vitamin D3 2,000 IU daily |
| BIOLOGICAL | Rituximab | Administered weekly x 4 |
| OTHER | Placebo | methylcellulose |
Timeline
- Start date
- 2017-09-07
- Primary completion
- 2023-07-21
- Completion
- 2024-07-02
- First posted
- 2017-03-13
- Last updated
- 2024-09-04
- Results posted
- 2024-09-04
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03078855. Inclusion in this directory is not an endorsement.